Table 2.

Clinical trials of CDK4/6 inhibitors in other tumors

CDK inhibitors	Study ID	Phase	Lines	Patients	Regimens	Efficacy
Palbociclib	NCT01209598 [47]	II	Non-first line	Advanced WD/DDLS	Palbociclib (n = 60)	PFS at 12 weeks 57.2%; mPFS 17.9 weeks
	NCT02101034 [46]	II	Non-first line	HNSCCs	Palbociclib + cetuximab (n = 62)	ORR 39% (in platinum-resistant patients), ORR 19% (in cetuximab-resistant patients)
	NCT01037790 (recruiting)	II	UK	RB/germ cell tumors	Palbociclib (n = 205)	PFS at 6 months 28%; mPFS 11 weeks
	NCT01536743 (active, not recruiting)	II	Non-first line	Ovarian epithelial carcinoma	Palbociclib (n = 26)	PFS at 6 months 15%
	NCT00420056 [48]	Ib	UK	MCL	Palbociclib (n = 17)	6% CR, 12% PR, 41% SD, mPFS 4.0 m
Ribociclib	CLEE011X2105 [45]	Ib/II	Non-first line	BRAF V600-mutant melanoma	Ribociclib (n = 18)	2 PR, 6 SD
	CMEK162X2114 [49]	Ib/II	UK	NRAS-mutant melanoma	Ribociclib + binimetinib (n = 22)	7 PR, 11 SD, 33% had 20–30% tumor shrinkage
Abemaciclib	NCT01394016 [44]	I	UK	Breast cancer; NSCLC; Melanoma; Glioblastoma; CRC	Abemaciclib (n = 225)	Breast cancer (n = 47) 23% PR, 47% SD, 23% ORR, 49% CBR, 70%DCR, mPFS 5.8 m; NSCLC (n = 68), 3% PR, 46% SD, 3% ORR, 49% DCR, mPFS 2.0 m; melanoma (n = 26) 4% PR, 23% SD, 4% ORR, 27% DCR; glioblastoma (n = 17) 18% SD, 18% DCR; CRC (n = 15) 13% SD, 13% DCR
	NCT02014129 [50]	I	Non-first line	Various advanced cancer	Abemaciclib (n = 12)	tumor size changed from 35% decrease to 25% increase, > 30% tumor shrinkage in 2 patients

WD/DDLS well-differentiated or dedifferentiated liposarcoma, HNSCCs head and neck squamous-cell carcinomas, Rb retinoblastoma, MCL mantle cell lymphoma, NSCLC non-small-cell lung cancer, CRC colorectal cancer, UK unknown, PFS progression-free survival, OS overall survival, ORR objective response rate, DCR disease control rate, CR complete response, PR partial response, SD stable disease, HR hazard ratio